seen from Türkiye
seen from Malaysia
seen from United States
seen from Denmark
seen from Netherlands
seen from Germany
seen from Armenia
seen from Spain
seen from United Kingdom
seen from Romania
seen from Germany
seen from United Kingdom
seen from Türkiye
seen from United States
seen from Russia
seen from Norway
seen from United States
seen from Netherlands
seen from United Kingdom
seen from United States
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. The BE MOBILE 2 trial, displayed a positive safety and efficacy results in patients who were affected by ankylosing spondylitis and poor response or intolerance to two nonsteroidal anti-inflammatory drugs and prior exposure to no more than one TNF inhibitor.
